| ObjectiveThe clinical characteristics of herpes zoster in patients with hematologic malignancies were analyzed and studied,in order to discover the relevant risk factors of patients with hematologic malignant tumors and herpes zoster and intervene in time,so as to provide potential hypothesis for preventive antiviral therapy.MethodsRetrospective analysis of 849 patients in total with leukemia,lymphoma and multiple myeloma who were hospitalized in the Department of Hematology Oncology from December 31,2017 to December 31,2022 in the First Affiliated Hospital of Dali University.31 cases with herpes zoster were selected as the research subjects,and 31 cases were randomly selected as control the remaining 818 cases without herpes zoster.Among the clinical characteristics including,as general data,treatment drugs,laboratory indicators,etc.In the patients with herpes zoster,grouping the patients again according to the primary disease.The analysis includes general data,the stage of myeloma patients(ISS stage,DS stage),the number of days of herpes zoster hospitalization,the chemotherapy cycle,the time from the first chemotherapy to the onset of herpes zoster,chemotherapy drugs,laboratory indicators and other indicators and the relationship between the occurrence of herpes zoster.The collected data is analyzed and processed through software such as SPSS 27.0 and Excel,and is considered to be statistically significant in P<0.05.Results1.In the analysis of 31 cases of hematologic malignant tumors combined with herpes zoster,herpes zoster mostly occurred in spring and summer,with an average age of 56 years,and the incidence of multiple myeloma was higher than that in the leukemia group and lymphoma group,and herpes zoster in the leukemia and multiple myeloma groups occurred in the first three cycles of chemotherapy.2.In the single-factor analysis of leukemia and herpes zoster,there were statistically significant differences between the two groups in absolute lymphocyte values,globulins,leukocyte ratio,uric acid,body weight,and body mass index(P<0.05).3.In the single-factor analysis of lymphoma combined with herpes zoster,no statistically significant indicators were found in general data,therapeutic drugs,laboratory indicators,etc.4.In the single-factor analysis of multiple myeloma and herpes zoster,there was a statistically significant difference between the two groups in absolute lymphocyte values and whether thalidomide was used(P<0.05).5.Multi-factor logistic regression analysis shows that the use of thalidomide is an independent risk factor in patients with multiple myeloma and herpes zoster and no independent risk factors were found in patients with leukemia and lymphoma and herpes zoster.Conclusions1.The risk of herpes zoster in multiple myeloma in hematologic malignancies is higher than that of leukemia and lymphoma,and herpes zoster in multiple myeloma and leukemia occurs more in the first three chemotherapy cycles.2.Decrease in absolute lymphocyte values may be a risk factor for herpes zoster in patients with hematologic malignancies.3.The use of thalidomide is an independent risk factor for herpes zoster in patients with multiple myeloma.4.For patients with hematologic malignant tumors,attention should be paid to the reactivation of varicella-zoster virus during treatment,and antiviral therapy should be started as soon as possible if necessary. |
PDF Full Text Request